RT Journal Article
SR Electronic
T1 mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.15.21263320
DO 10.1101/2021.09.15.21263320
A1 Veerle P. W. M. Wijtvliet
A1 Kevin K. Ariën
A1 Steven Abrams
A1 Marie M. Couttenye
A1 Fabienne Mestrez
A1 Joachim Mariën
A1 Benedicte Y. De Winter
A1 Pierre Van Damme
A1 Lissa Pipeleers
A1 Karl Martin Wissing
A1 Daniel Abramowicz
A1 Kristien J. Ledeganck
YR 2021
UL http://medrxiv.org/content/early/2021/11/16/2021.09.15.21263320.abstract
AB In this study of the humoral immune response after the SARS-CoV-2 mRNA vaccination, low seroconversion rates were noted in both kidney transplant recipients and dialysis patients after first dose administration. While in DP the seroconversion rate levelled up to 92.8% after a second dose of SARS-CoV-2 mRNA vaccination, KTR stayed behind with a seroconversion rate of 62.4%. Futhermore, vaccination with the mRNA-1273 vaccine (Moderna) resulted in both higher seroconversion rates and mean log-transformed antibody titer concentrations compared to BNT162b2 (Pfizer).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicableFunding StatementThe authors received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Antwerp University HospitalI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for original and additional data should be directed to the corresponding author.